Two Tales: One Story.

Approximately 17% of patients discontinued therapy in EMPEROR-Reduced (versus 11% in DAPA-HF), and vital status was unknown in 21 patients in EMPERORReduced (versus 2 in DAPA-HF). Baseline estimated glomerular filtration rate (eGFR) was lower in EMPEROR-Reduced ( 61 mL-min -1 -1.73 m -2) compared with DAPA-HF ( 66 mL-min -1 -1.73 m -2), and proportionally more EMPEROR-Reduced patients had an eGFR that was <=60 mL-min -1 -1.73 m -2. As a reflection of these differences in patient populations, the placebo event rates also differed between the 2 trials. [Extracted from the article]